---
aliases:
- (King et al., 2022)
author: King, Amanda L. and Shuboni-Mulligan, Dorela D. and Vera, Elizabeth and Crandon,
  Sonja and Acquaye, Alvina A. and Boris, Lisa and Burton, Eric and Choi, Anna and
  Christ, Alexa and Grajkowska, Ewa and Jammula, Varna and Leeper, Heather E. and
  Lollo, Nicole and Penas-Prado, Marta and Reyes, Jennifer and Theeler, Brett and
  Wall, Kathleen and Wu, Jing and Gilbert, Mark R. and Armstrong, Terri S.
citekey: king2022ExploringPrevalenceBurden
date_added: '2025-03-23'
doi: 10.1093/nop/npac049
journal: Neuro-Oncology Practice
title: Exploring the Prevalence and Burden of Sleep Disturbance in Primary Brain Tumor
  Patients
year: '2022'

---
# Exploring the Prevalence and Burden of Sleep Disturbance in Primary Brain Tumor Patients
- [PDF Link](zotero://open-pdf/library/items/LQNZB3SM)

Citation: [@king2022ExploringPrevalenceBurden]

***
# TL;DR (Summary)
- 19% of primary brain tumor (PBT) patients reported moderate-severe sleep disturbance (SD).
- Patients with moderate-severe SD were on average 4.8 years younger than those with none-mild SD (P = .005).
- Patients with poor Karnofsky Performance Status (KPS ≤80) were 2.2 times more likely to report moderate-severe SD (P = .002).
- Those with tumor progression on MRI were twice as likely to report moderate-severe SD (P = .012).
- Patients on corticosteroids were 2.4 times more likely to report moderate-severe SD (P = .002).
- Moderate-severe SD patients reported a 2.2-point higher symptom burden score on the MDASI-BT (P < .001).
- Patients with moderate-severe SD reported 3 to 4 times higher prevalence of depressive and anxiety symptoms, respectively.
- Utilized data from the Natural History Study (NHS) clinical trial to explore SD in PBT patients, providing a large sample size and high response rate for self-reported outcomes.
- Authors suggest that SD may serve as a bridge symptom affecting the development and severity of other symptoms in PBT patients.
- Emphasize the need for future longitudinal studies to better understand SD fluctuations over the illness trajectory.
- Recommend exploring biological mechanisms, including genetic influences and circadian rhythms, to understand SD in PBT patients.
- SD co-occurred with symptoms indicative of tumor progression, such as cognitive changes, pain, and visual changes.
- The study highlights the importance of using comprehensive symptom instruments to capture SD and related symptoms longitudinally.

# 中文摘要 (TL;DR)
- 19% 的原發性腦瘤（PBT）患者報告中度至重度睡眠障礙（SD）。
- 中度至重度SD的患者平均比無或輕度SD的患者年輕4.8歲（P = .005）。
- 卡諾夫斯基表現狀態（KPS ≤80）較差的患者報告中度至重度SD的可能性高2.2倍（P = .002）。
- 在MRI上顯示腫瘤進展的患者報告中度至重度SD的可能性是其兩倍（P = .012）。
- 使用皮質類固醇的患者報告中度至重度SD的可能性高2.4倍（P = .002）。
- 中度至重度SD患者在MDASI-BT上的症狀負擔得分高出2.2分（P < .001）。
- 中度至重度SD患者報告抑鬱和焦慮症狀的患病率分別高出3到4倍。
- 利用自然病史研究（NHS）臨床試驗的數據來探索PBT患者的SD，提供了大樣本量和高自我報告結果的響應率。
- 作者建議SD可能作為一種橋接症狀，影響PBT患者其他症狀的發展和嚴重程度。
- 強調需要未來的縱向研究以更好地理解SD在病程中的波動。
- 建議探索包括遺傳影響和晝夜節律在內的生物機制，以理解PBT患者的SD。
- SD與表示腫瘤進展的症狀共現，如認知變化、疼痛和視覺變化。
- 該研究強調使用綜合症狀工具來捕捉SD及其相關症狀的縱向重要性。
